Literature DB >> 24225970

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

Ayal A Aizer1, Jonathan J Paly, Anthony L Zietman, Paul L Nguyen, Clair J Beard, Sandhya K Rao, Irving D Kaplan, Andrzej Niemierko, Michelle S Hirsch, Chin-Lee Wu, Aria F Olumi, M Dror Michaelson, Anthony V D'Amico, Jason A Efstathiou.   

Abstract

NCCN Guidelines recommend active surveillance as the primary management option for patients with very-low-risk prostate cancer and an expected survival of less than 20 years, reflecting the favorable prognosis of these men and the lack of perceived benefit of immediate, definitive treatment. The authors hypothesized that care at a multidisciplinary clinic, where multiple physicians have an opportunity to simultaneously review and discuss each case, is associated with increased rates of active surveillance in men with very-low-risk prostate cancer, including those with limited life expectancy. Of 630 patients with low-risk prostate cancer managed at 1 of 3 tertiary care centers in Boston, Massachusetts in 2009, 274 (43.5%) had very-low-risk classification. Patients were either seen by 1 or more individual practitioners in sequential settings or at a multidisciplinary clinic, in which concurrent consultation with 2 or more of the following specialties was obtained: urology, radiation oncology, and medical oncology. Patients seen at a multidisciplinary prostate cancer clinic were more likely to select active surveillance than those seen by individual practitioners (64% vs 30%; P<.001), an association that remained significant on multivariable logistic regression (odds ratio [OR], 4.16; P<.001). When the analysis was limited to patients with an expected survival of less than 20 years, this association remained highly significant (72% vs 34%, P<.001; OR, 5.19; P<.001, respectively). Multidisciplinary care is strongly associated with selection of active surveillance, adherence to NCCN Guidelines and minimization of overtreatment in patients with very-low-risk prostate cancer.

Entities:  

Mesh:

Year:  2013        PMID: 24225970     DOI: 10.6004/jnccn.2013.0160

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  5 in total

1.  Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.

Authors:  Claudio Jeldres; Jennifer Cullen; Lauren M Hurwitz; Erika M Wolff; Katherine E Levie; Katherine Odem-Davis; Richard B Johnston; Khanh N Pham; Inger L Rosner; Timothy C Brand; James O L'Esperance; Joseph R Sterbis; Ruth Etzioni; Christopher R Porter
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

2.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Authors:  Donna P Ankerst; Josef Hoefler; Sebastian Bock; Phyllis J Goodman; Andrew Vickers; Javier Hernandez; Lori J Sokoll; Martin G Sanda; John T Wei; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2014-06       Impact factor: 2.649

3.  Longitudinal evaluation of apparent diffusion coefficient values as a predictor of Prostate Cancer Research International Active Surveillance reclassification.

Authors:  Eri Ota; Naoko Mori; Shinichi Yamashita; Shunji Mugikura; Akihiro Ito; Kei Takase
Journal:  Abdom Radiol (NY)       Date:  2021-12-09

4.  Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.

Authors:  Jung Ki Jo; Han Sol Lee; Young Ik Lee; Sang Eun Lee; Sung Kyu Hong
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

5.  Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Authors:  Kittie Pang; Margaret Fitch; Veronique Ouellet; Simone Chevalier; Darrel E Drachenberg; Antonio Finelli; Jean-Baptiste Lattouf; Alan So; Simon Sutcliffe; Simon Tanguay; Fred Saad; Anne-Marie Mes-Masson
Journal:  BMC Health Serv Res       Date:  2018-06-08       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.